Tarsus Pharmaceuticals (TARS) Stock: Buy, Sell, or Hold?
TARS - Tarsus Pharmaceuticals, Inc. Common Stock
$79.31
-1.81 (-2.23%)
▼
5d:
-4.68%
30d:
+13.28%
90d:
+26.67%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When TARS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TARS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TARS shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$84.63
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$52.55
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TARS is currently trading at $79.31, which is considered extended relative to its 30-day fair value range of $63.99 to $78.85. The stock's valuation (Forward PE: 32.8) is in line with its historical norms (34.9). Remarkably, the market is currently pricing in an annual earnings decline of 2.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, TARS is in a uptrend. Immediate support is located at $70.71, while resistance sits at $91.53.
Market Sentiment: TARS scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $96.12 (+21.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TARS is in a uptrend. Immediate support is located at $70.71, while resistance sits at $91.53.
Market Sentiment: TARS scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $96.12 (+21.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$63.99 -
$78.85
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
28.6%
Protect Your Profits
Holding TARS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 21.2% below Wall St target ($96.12)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$63.99 -
$78.85
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$70.71
Resistance Level
$91.53
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
32.83
Wall Street Target
$96.13
(+21.2%)
Revenue Growth (YoY)
69.4%
Profit Margin
-7.7%
Valuation Discount vs History
-2.0% cheaper
PE vs Historical
32.8 vs 34.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.0%
(market-implied from PE analysis)
1-Year Target
$77.72
(-2%)
2-Year Target
$76.17
(-4%)
3-Year Target
$74.65
(-6%)
3-Yr Target (if PE normalizes)
(PE: 33→35)
$79.36
(+0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 32.8 to 34.9
Stabilization Target:
$84.32
(+6.3%)
PE Expansion Potential:
+6.3%
Share & Embed Analysis
Last updated: September 13, 2026 5:22 PM ET
Data refreshes hourly during market hours. Next update: 6:22 PM
Data refreshes hourly during market hours. Next update: 6:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TARS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Bryan Wahl
SELL
4231 shares
2026-03-19
Dianne C Whitfield
SELL
4174 shares
2026-03-19
Elizabeth Yeu Lin
SELL
390 shares
2026-03-19
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$849 | 50 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$290 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
Advanced TARS Option Strategies
Professional options setups generated by AI based on today's TARS price and gamma walls.
